Advertisement
Abbott Laboratories
Subscribe to Abbott Laboratories

The Lead

Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

September 15, 2014 10:49 am | by PR Newswire | News | Comments

Abbott announced today positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic...

New Technology May Uncover the Root of Critical Infections and Cut Healthcare Costs

September 8, 2014 10:19 am | by PR Newswire | News | Comments

A new study suggests a pioneering testing technology could reduce hospital stays by up to eight...

Abbott & DOD to Develop Portable Blood Tests for Evaluating Concussions

August 18, 2014 10:00 am | by PR Newswire | News | Comments

Abbott and the United States Department of Defense have announced a collaboration with the...

Photos of the Day: Concussion Blood Test

August 18, 2014 9:59 am | by Abbott | News | Comments

Abbott's handheld, diagnostic analyzer is capable of performing a panel of commonly ordered...

View Sample

FREE Email Newsletter

This Rainbow Leads to New Medical Innovations

June 27, 2014 2:45 pm | by Bloomberg | Videos | Comments

Efi Cohen-Arazi, co-founder and Chief Executive Officer at Rainbow Medical, talks with Elliott Gotkine about innovations to help those who have lost their vision and their partnership with Medtronic on a nerve stimulation product. He speaks...

CE Mark for Abbott’s Extended Range of Vision Intraocular Lens for Cataract Patients

June 24, 2014 10:35 am | by Abbott | News | Comments

Abbott announced it has received CE Marking (Conformité Européenne) in Europe for the TECNIS Symfony Extended Range of Vision intraocular lens (IOL) for the treatment of cataract patients who may also have a diminished ability to focus...

Report on Medical Device Market Outlines Challenges, Opportunities for Cost Containment

May 30, 2014 3:44 pm | by Rich Gedney, CEO, ADMET | Admet, Inc. | Blogs | Comments

The medical device market has experienced tremendous growth, reaching more than $330 billion worldwide. While the industry remains healthy, several challenges face those who design and manufacture medical devices. ADMET serves this market...

Advertisement

Recall Report: Door Assemblies in Infusion Pumps May Break

May 5, 2014 10:02 am | by Food and Drug Administration (FDA) | News | Comments

Hospira received customer reports of broken door assemblies on the Abbott Acclaim infusion pumps and the Hospira Acclaim Encore infusion pumps. When the door is closed properly, it helps ensure that the tubing is seated properly to ensure...

Abbott Receives 510(k) for Test to Help Diagnose Diabetes

April 14, 2014 11:31 am | by Abbott | News | Comments

Abbott announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test - which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease - has received 510(k) clearance...

Opportunities and Challenges of Doing Business in Companion Diagnostics

April 14, 2014 9:56 am | by Richard Park, Contributing Editor | Blogs | Comments

For my occasional series of blogs examining various facets of the companion diagnostics market, I asked some of the major IVD manufacturers to share their thoughts and opinions on the current opportunities and challenges in companion...  

Abbott Completes Enrollment of AbsorbT Randomized Clinical Trials in the U.S., Japan, and China

April 10, 2014 8:31 am | by The Associated Press | News | Comments

Abbott has announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary AbsorbT Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and...

Abbott Announces FDA Approval of Its Supera Stent to Treat People with Peripheral Artery Disease

March 28, 2014 12:36 pm | by The Associated Press | News | Comments

Abbott has announced that its Supera Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). PAD occurs when...

Advertisement

Abbott shutters Puerto Rico facility

January 31, 2014 2:04 pm | by Mass Device | News | Comments

Abbott is reportedly shutting down a Puerto Rico manufacturing plant, with an unspecified number of employees slated for termination. The plant in question resides in a city called Barceloneta, and the facility houses pharmaceutical...  

Class I Medical Device Recall: Abbott Diabetes Care, FreeStyle and FreeStyle Lite Blood Glucose Test Strips - Erroneously Low Blood Glucose Results

January 6, 2014 12:00 am | by U.S. Food & Drug Administration | News | Comments

Affected FreeStyle and FreeStyle Lite Blood Glucose Test Strips may deliver erroneously low blood glucose results when used with the FreeStyle Flash Blood Glucose Meter, FreeStyle Blood Glucose Meter, and the FreeStyle Blood Glucose Meter...

Abbott Issues Voluntary Recall of Blood Glucose Test Strips

December 3, 2013 11:31 am | by FDA | News | Comments

Abbott has announced it is initiating a voluntary recall of 20 lots of FreeStyle and FreeStyle Lite Blood Glucose Test Strips in the United States. These lots of test strips may produce erroneously low blood glucose results when used with both...

Diabetes: Abbott recalls blood glucose test strips

December 2, 2013 1:58 pm | by Mass Device | News | Comments

Abbott Diabetes Care said it issued a recall of its FreeStyle blood glucose test strips after reports of falsely low results. The Alameda, Calif.-based medical device company found that the FreeStyle test strips used with Insulet's OmniPod...

Abbott's First-In-Class MitraClip Device Available for U.S. Patients

October 25, 2013 9:05 am | by The Associated Press | News | Comments

Abbott today announced that its first-in-class, catheter-based MitraClip therapy has received U.S. Food and Drug Administration (FDA) approval and will launch immediately in the United States, providing physicians with a breakthrough treatment...

Advertisement

Therapeutic Coatings for Medical Device Implants

October 1, 2013 3:27 pm | by Nathan Lockwood, Ph.D., Senior Manager of R&D, SurModics Inc. | SurModics, Inc. | Articles | Comments

Drug delivery coatings are not a new technology to the medical device industry. However, as more implantable devices are tasked with achieving a greater level of healthcare, they do offer great benefit to design engineers. This article reviews drug coating technology and looks at application areas where it has made a significant impact.

CE Mark for Abbott’s Blood Glucose and Ketone Monitoring System

September 20, 2013 9:32 am | by Abbott | News | Comments

Abbott announced today it has received CE Marking in Europe for the FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™. The new icon-driven system provides sleek design, visual glucose trend indicators and insulin logging – all delivered in a single device to support daily diabetes management.

Abbott's Test May Offer More Accurate Diagnosis of Heart Attacks in Women

September 5, 2013 10:41 am | by Abbott | News | Comments

Abbott announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack.

GPOs: Medtronic, St. Jude, Boston Scientific land new deals from Premier

August 13, 2013 12:27 pm | by Mass Device | News | Comments

Premier Healthcare Alliance awarded several new contracts for drug-eluting stents, traditional stents and other intervention products to 8 heavy hitters in the cardiology space. Abbott, Boston Scientific, and Medtronic all landed supplier deals for drug-eluting and traditional stents.

Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and β–Ketone Monitoring System

July 29, 2013 11:09 am | by Abbott | News | Comments

Abbott has announced that it has received U.S. FDA clearance for its FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System, an advanced blood glucose monitoring system designed to address the key needs of hospital customers: high accuracy, efficient operation, dual-band wireless access to immediate test results, and helps in the reduction of the risk of test strip cross-contamination.

Abbott's Q2 sales tick up, earnings beat Wall Street

July 17, 2013 10:04 am | by Mass Device | News | Comments

Abbott missed expectations with its 2nd-quarter sales but still managed to exceed earnings forecasts, sending shares up this morning on Wall Street. The Chicago-area company posted profits of $476 million, or 64¢ per share, on sales of $5.45 billion during the 3 months ended June 30, for sales growth of 2.5% but a bottom-line slide of 72.4%.

Abbott Will Pay $560M to Acquire 2 Med Tech Firms

July 15, 2013 11:45 am | by The Associated Press | News | Comments

Abbott Laboratories announced Monday it would pay a combined $560 million to acquire two privately-held companies focused on coronary implants and laser-assisted eye surgery. The acquisitions of Idev Technologies and OptiMedica Corp will help the health care company expand its medical device offerings.

Abbott to Acquire IDEV Technologies to Expand Global Peripheral Technology Portfolio

July 15, 2013 8:30 am | by PR Newswire | News | Comments

Abbott today announced that it has entered into an agreement to purchase IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and cardiologists. Under the terms of the agreement, Abbott will acquire all outstanding equity of IDEV Technologies for $310 million net of cash and debt.

Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the AbsorbT Bioresorbable Vascular Scaffold

June 11, 2013 9:30 am | by The Associated Press | News | Comments

Abbott (NYSE: ABT) today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the AbsorbT Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most common form of heart disease.

Analyst: FDA OK Unlikely for Abbott Heart Device

March 21, 2013 1:09 pm | by The Associated Press | News | Comments

A medical device industry analyst says Abbott Laboratories is unlikely to win approval anytime soon for its device used to repair heart valve problems, following a tepid endorsement by government experts. A Food and Drug Administration panel of heart experts voted 5-3 on Wednesday that the...

FDA Advisory Committee Votes Favorably on Abbott's Minimally Invasive MitraClip® Device for Patients with Significant Mitral Regurgitation Who Are Too High Risk for Surgery

March 20, 2013 7:44 pm | by PR Newswire | News | Comments

ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of...

FDA Panel Votes 5-3 that Benefits of Abbott's MitraClip Heart Implant Outweigh the Risks

March 20, 2013 6:55 pm | by Mass Device | News | Comments

The FDA's Circulatory System Devices Panel voted today to make its recommendation regarding Abbott's (NYSE:ABT) premarket approval application for the MitraClip heart implant, agreeing unanimously that the device is safe but issuing a mixed result on the effectiveness and potential risks of the device.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading